BTG takes a hit after Astra halts CytoFab development

Specialist healthcare group BTG revealed on Tuesday that it will take a one-off charge after disappointing results from its 'CytoFab' study meant that further development of the drug has been halted.

Specialist healthcare group BTG revealed on Tuesday that it will take a one-off charge after disappointing results from its 'CytoFab' study meant that further development of the drug has been halted.

The group has received top-line data from an AstraZeneca study comparing the efficacy and safety of AZD9773 with a placebo. AZD9773, or CytoFab, is a developing treatment for severe sepsis and/or septic shock.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up
MoneyWeek

MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.